Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
J Trace Elem Med Biol. 2020 Jul;60:126499. doi: 10.1016/j.jtemb.2020.126499. Epub 2020 Mar 16.
Diagnosis and treatment of complex diseases such as Neurodevelopmental Disorders (NDDs) can be resolved through the identification of biomarkers. Metallomics (research on biometals) and metallomes (metalloproteins/metalloenzymes/chaperones) along with genomics, proteomics and metabolomics, can contribute to accelerate and improve this process.
This review focused on four NDDs pathologies (Schizophrenia, SZ; Attention Deficit Hyperactivity Disorder, ADHD; Autism, ADS; Epilepsy), and we reported, for the first time, different studies on the role played by the principal six essential trace elements (Cobalt, Co; Copper, Cu; Iron, Fe; Manganese, Mn; Selenium, Se; Zinc, Zn) that can influence diagnosis/treatment.
in light of the literature presented, based on meta-analyses, we suggest that Zn (glutamatergic neurotransmission, inflammation, neurodegeneration, autoimmunity alterations), could be a potential diagnostic biomarker associated to SZ. Moreover, considering the single association studies going in the same direction, increased Cu (catecholamine alterations, glucose intolerance, altered lipid metabolism/oxidative stress) and lower Fe (dopaminergic dysfunctions) levels were associated with a specific negative symptomatology. Lower Mn (lipid metabolism/oxidative stress alterations), and lower Se (metabolic syndrome) were linked to SZ. From the meta-analyses in ADHD, it is evidenced that Fe (and ferritin in particular), Mn, and Zn (oxidative stress dysfunctions) could be potential diagnostic biomarkers, mainly associated to severe hyperactive or inattentive symptoms; as well as Cu, Fe, Zn in ADS and Zn in Epilepsy. Fe, Zn and Mn levels seem to be influenced by antipsychotics treatment in SZ; Mn and Zn by methylphenidate treatment in ADHD; Cu and Zn by antiepileptic drugs in Epilepsy.
Although there is controversy and further studies are needed, this work summarizes the state of art of the literature on this topic. We claim to avoid underreporting the impact of essential trace elements in paving the way for biomarkers research for NDDs.
神经发育障碍(NDD)等复杂疾病的诊断和治疗可以通过生物标志物的鉴定来解决。金属组学(生物金属研究)和金属组(金属蛋白/金属酶/伴侣蛋白)与基因组学、蛋白质组学和代谢组学一起,可以加速和改善这一过程。
本综述重点关注四种 NDD 病理(精神分裂症、SZ;注意缺陷多动障碍、ADHD;自闭症、ADS;癫痫),我们首次报道了关于六种主要必需微量元素(钴、Cu;铜、Cu;铁、Fe;锰、Mn;硒、Se;锌、Zn)在影响诊断/治疗方面的作用的不同研究。
根据文献综述,基于荟萃分析,我们提出 Zn(谷氨酸能神经传递、炎症、神经退行性变、自身免疫改变)可能是与 SZ 相关的潜在诊断生物标志物。此外,考虑到方向一致的单一关联研究,增加的 Cu(儿茶酚胺改变、葡萄糖耐量异常、脂质代谢/氧化应激改变)和较低的 Fe(多巴胺能功能障碍)水平与特定的阴性症状相关。较低的 Mn(脂质代谢/氧化应激改变)和较低的 Se(代谢综合征)与 SZ 有关。从 ADHD 的荟萃分析中可以看出,Fe(尤其是铁蛋白)、Mn 和 Zn(氧化应激功能障碍)可能是潜在的诊断生物标志物,主要与严重多动或注意力不集中的症状有关;以及 Cu、Fe、Zn 在 ADS 中,Zn 在癫痫中。Fe、Zn 和 Mn 水平似乎受到 SZ 中抗精神病药物治疗的影响;Mn 和 Zn 受 ADHD 中哌醋甲酯治疗的影响;Cu 和 Zn 受癫痫中抗癫痫药物治疗的影响。
尽管存在争议,需要进一步研究,但这项工作总结了该主题文献的最新进展。我们主张避免低估必需微量元素在为 NDD 生物标志物研究铺平道路方面的影响。